Research graph
References from Genetic evidence supports a cortical neuroprotective role of GLP‐1 receptor activation in Alzheimer's disease: A drug‐target Mendelian randomization study. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent advances in Alzheimer's disease: mechanisms, clinical trials and new drug development strategies
10.1038/s41392-024-01911-3 · 2024 · External reference
Lecanemab in Early Alzheimer's Disease
10.1056/nejmoa2212948 · 2023 · External reference
Donanemab in Early Symptomatic Alzheimer Disease: the TRAILBLAZER‐ALZ 2 Randomized Clinical Trial
10.1001/jama.2023.13239 · 2023 · External reference
Efficacy and Safety of GLP‐1 Medicines for Type 2 Diabetes and Obesity
10.2337/dci24-0003 · 2024 · External reference
Repurposing glucagon‐like peptide‐1 receptor agonists for the treatment of neurodegenerative disorders
10.1038/s43587-025-01029-3 · 2026 · External reference
The promise of GLP‐1 receptor agonists for neurodegenerative diseases
10.1172/jci194745 · 2026 · External reference
Role of Glucagon‐Like Peptide‐1 on Amyloid, Tau, and α‐Synuclein: target Engagement and Rationale for the Development in Neurodegenerative Disorders
10.1016/j.neubiorev.2025.106159 · 2025 · External reference
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
2022 · External reference
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real‐world data in the US
10.1002/alz.14313 · 2024 · External reference
GLP‐1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
10.1001/jamaneurol.2025.0353 · 2025 · External reference
Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial
10.1038/s41591-025-04106-7 · 2026 · External reference
evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early‐stage symptomatic Alzheimer's disease
10.1186/s13195-024-01666-7 · 2025 · External reference
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early‐stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo‐controlled trials
10.1016/s0140-6736(26)00459-9 · 2026 · External reference
Are Glucagon‐Like Peptide‐1 (GLP‐1) Receptor Agonists Central Nervous System (CNS) Penetrant: a Narrative Review
10.1007/s40120-025-00724-y · 2025 · External reference
Glycated hemoglobin and body mass index as mediators of GLP‐1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes
10.1002/alz.70161 · 2025 · External reference
‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease
10.1093/ije/dyg070 · 2003 · External reference
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
2014 · External reference
Mendelian Randomization
10.1001/jama.2017.17219 · 2017 · External reference
Genetic drug target validation using Mendelian randomisation
10.1038/s41467-020-16969-0 · 2020 · External reference
Genetic variation in targets of antidiabetic drugs and alzheimer disease risk: a mendelian randomization study
10.1212/wnl.0000000000200771 · 2022 · External reference
Genetic evidence for repurposing of GLP1R (Glucagon‐Like Peptide‐1 Receptor) agonists to prevent heart failure
10.1161/jaha.120.020331 · 2021 · External reference
Metabolic improvement mediates the causal relationship between glp‐1 receptor agonists and myocardial infarction: a mendelian randomization and mediation analysis study
10.2337/dc25-1822 · 2026 · External reference
Selecting likely causal risk factors from high‐throughput experiments using multivariable Mendelian randomization
10.1038/s41467-019-13870-3 · 2020 · External reference
GLP‐1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
10.1093/eurheartj/ehaf1066 · 2026 · External reference
The GTEx Consortium atlas of genetic regulatory effects across human tissues
10.1126/science.aaz1776 · 2020 · External reference
Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain‐related diseases
10.1038/s41588-023-01300-6 · 2023 · External reference
Genetic meta‐analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing
10.1038/s41588-019-0358-2 · 2019 · External reference
New insights into the genetic etiology of Alzheimer's disease and related dementias
10.1038/s41588-022-01024-z · 2022 · External reference
Genome‐wide association study and functional characterization identifies candidate genes for insulin‐stimulated glucose uptake
10.1038/s41588-023-01408-9 · 2023 · External reference
Mechanisms of action of glucagon‐like peptide 1 in the pancreas
10.1016/j.pharmthera.2006.11.007 · 2007 · External reference
Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program
10.1126/science.adj1182 · 2024 · External reference
Genetic analysis of over half a million people characterises C‐reactive protein loci
10.1038/s41467-022-29650-5 · 2022 · External reference
Orienting the causal relationship between imprecisely measured traits using GWAS summary data
10.1371/journal.pgen.1007081 · 2017 · External reference
Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants
10.1093/ije/dyq151 · 2011 · External reference
Bayesian test for colocalisation between pairs of genetic association studies using summary statistics
10.1371/journal.pgen.1004383 · 2014 · External reference
Guidelines for performing Mendelian randomization investigations: update for summer 2023
10.12688/wellcomeopenres.15555.3 · 2023 · External reference
Combining evidence from Mendelian randomization and colocalization: review and comparison of approaches
10.1016/j.ajhg.2022.04.001 · 2022 · External reference
The MR‐Base platform supports systematic causal inference across the human phenome
10.7554/elife.34408 · 2018 · External reference
LDlinkR: an R Package for Rapidly Calculating Linkage Disequilibrium Statistics in Diverse Populations
10.3389/fgene.2020.00157 · 2020 · External reference
The NHGRI‐EBI GWAS Catalog: knowledgebase and deposition resource
10.1093/nar/gkac1010 · 2023 · External reference
The power of genetic diversity in genome‐wide association studies of lipids
10.1038/s41586-021-04064-3 · 2021 · External reference
A multivariable cis‐Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias
10.1093/bib/bbaf250 · 2025 · External reference
MRBEE: a bias‐corrected multivariable Mendelian randomization method
2024 · External reference
EPIC‐InterAct Consortium. Network Mendelian randomization: using genetic variants as instrumental variables to investigate mediation in causal pathways
10.1093/ije/dyu176 · 2015 · External reference
Mendelian randomisation for mediation analysis: current methods and challenges for implementation
10.1007/s10654-021-00757-1 · 2021 · External reference
Cardioprotective Glucose‐Lowering Agents and Dementia Risk: a Systematic Review and Meta‐Analysis
10.1001/jamaneurol.2025.0360 · 2025 · External reference
Effect of glucagon‐like peptide‐1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta‐analysis
10.1016/j.clinthera.2014.11.008 · 2015 · External reference
Comparative effectiveness of GLP‐1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta‐analysis
10.1136/bmj-2023-076410 · 2024 · External reference
Glucagon‐like peptide 1 receptor agonists modestly reduced low‐density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta‐analysis and meta‐regression of placebo controlled randomized controlled trials
10.1080/03007995.2024.2442027 · 2025 · External reference
Glucagon‐like peptide 1 (GLP‐1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta‐analysis of preclinical studies
10.3389/fphar.2023.1205207 · 2023 · External reference
Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase‐3β pathway in an amyloid β protein induced alzheimer disease mouse model
10.1016/j.ejphar.2016.04.052 · 2016 · External reference
Dulaglutide ameliorates STZ induced AD‐like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β
10.1016/j.bbrc.2019.01.103 · 2019 · External reference
Glucagon‐like peptide‐1 decreases endogenous amyloid‐beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron
10.1002/jnr.10611 · 2003 · External reference
GLP‐1 receptor stimulation reduces amyloid‐beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease
10.3233/jad-2010-1314 · 2010 · External reference
The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease
10.1523/jneurosci.0529-11.2011 · 2011 · External reference
Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
10.1016/j.neuropharm.2013.08.005 · 2014 · External reference
Long‐Term Treatment with Liraglutide, a Glucagon‐Like Peptide‐1 (GLP‐1) Receptor Agonist, Has No Effect on β‐Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease
10.1371/journal.pone.0158205 · 2016 · External reference
The GLP‐1 medicines semaglutide and tirzepatide do not alter disease‐related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
10.1016/j.molmet.2024.102019 · 2024 · External reference
Apparent thinning of human visual cortex during childhood is associated with myelination
10.1073/pnas.1904931116 · 2019 · External reference
Glucagon‐Like Peptide‐1 Receptor Agonists as Potential Myelination‐Inducible and Anti‐Demyelinating Remedies
10.3389/fcell.2022.950623 · 2022 · External reference
Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome
10.1007/s10787-022-00956-6 · 2022 · External reference
Blood‐brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: evidence from a cohort study
10.1016/j.jalz.2016.09.006 · 2017 · External reference
Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment
10.1186/s40478-023-01590-1 · 2023 · External reference
Hypertension, Neurodegeneration, and Cognitive Decline
10.1161/hypertensionaha.123.21356 · 2024 · External reference
Heterogeneous blood‐brain barrier dysfunction in cerebral small vessel diseases
10.1002/alz.13874 · 2024 · External reference
GLP‐1 Receptor Agonists and Blood Pressure: a State‐of‐the‐Art Review of Mechanisms, Evidence, and Clinical Implications
10.1093/ajh/hpaf205 · 2026 · External reference
Endothelial GLP‐1 (Glucagon‐Like Peptide‐1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension
10.1161/atv.0000615456.97862.30 · 2020 · External reference
